PT - JOURNAL ARTICLE AU - Dalhuisen, Thomas AU - Grebe, Halle AU - Anglin, Khamal AU - Lu, Scott AU - Goldberg, Sarah A. AU - Kallás-Silva, Lucas AU - Hauser, Joshua AU - Conway, Emily AU - Ewing, Marin AU - Chen, Jessica Y. AU - Fehrman, Emily A. AU - Kelly, J. Daniel AU - Martin, Jeffrey N. AU - Hunt, Peter W. AU - Henrich, Timothy J. AU - Durstenfeld, Matthew S. AU - Deeks, Steven G. AU - Murphy, Elizabeth AU - Schambelan, Morris AU - Peluso, Michael J. TI - Relationship between plasma cortisol concentration and Long COVID symptoms in the post-acute phase of COVID-19: a cross-sectional study and recommendations for future research AID - 10.1101/2024.11.07.24316777 DP - 2024 Jan 01 TA - medRxiv PG - 2024.11.07.24316777 4099 - http://medrxiv.org/content/early/2024/11/08/2024.11.07.24316777.short 4100 - http://medrxiv.org/content/early/2024/11/08/2024.11.07.24316777.full AB - BACKGROUND Low cortisol concentrations have been reported in some people with Long COVID (LC), but more data from diverse cohorts are needed to validate this observation. A subset of people with LC present with symptoms resembling those of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). The objective of this study was to compare cortisol concentrations in those with and without Long COVID, with a particular focus on people experiencing ME/CFS-like Long COVID.METHODS We measured plasma cortisol in 200 individuals 3-6 months following a SARS-CoV-2 infection. Banked biospecimens collected between 8 AM-12 PM were used. Participants met the case definition for Long COVID if they had ≥1 COVID-attributed symptom at least 3 months after symptom onset. People who did not report any symptoms at least 3 months after symptom onset served as recovered controls. Adapting the 2015 Institute of Medicine criteria for ME/CFS, we further defined those with LC resembling ME/CFS (LC-ME).RESULTS We found no difference in overall morning cortisol concentrations between people with LC (n=144) and those who fully recovered (n=56) (median 8.9 µg/dL vs. 8.8 µg/dL, p=0.97). Analyses of samples collected between 8-10 AM, however, revealed that, compared to those who fully recovered, cortisol concentrations were lower between 8-9 AM for those with LC-ME (median 8.2 vs. 14.8, p=0.02), but higher between 9-10 AM for those with severe LC (>=5 symptoms) (median 12.4 vs. 8.5, p=0.009) and those with LC-ME (median 13.7 vs. 8.5, p=0.02).CONCLUSION We found no difference in overall morning plasma cortisol concentrations between those with and without Long COVID. Although our data could be suggestive of altered morning cortisol dynamics in a subset of people with Long COVID, longitudinal measures of cortisol in individuals with Long COVID will be critical to further inform the biology of the condition.Competing Interest StatementSGD reports consulting for Enanta Pharmaceuticals and Pfizer and reports research support from Aerium Therapeutics outside the submitted work. MJP has received consulting fees from Gilead Sciences, AstraZeneca, BioVie, Apellis Pharmaceuticals, and BioNTech and research support from Aerium Therapeutics and Shionogi, outside the submitted work.Funding StatementMJP is supported on K23AI157875. The LIINC clinical core is supported by the PolyBio Research Foundation, with additional funding from R01AI141003 (to TJH) and 1R01NS136197 (to MJP).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the UCSF Institutional Review Board.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.